A New Method for Detecting Associations with Rare Copy-Number Variants by Tzeng, Jung-Ying et al.
RESEARCH ARTICLE
A New Method for Detecting Associations
with Rare Copy-Number Variants
Jung-Ying Tzeng1,2, Patrik K. E. Magnusson3, Patrick F. Sullivan3,4, The Swedish
Schizophrenia Consortium¶, Jin P. Szatkiewicz3*
1 Department of Statistics and Bioinformatics Research Center, North Carolina State University, Raleigh,
North Carolina, United States of America, 2 Department of Statistics, National Cheng-Kung University,
Tainan, Taiwan, 3 Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North
Carolina, United States of America, 4 Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm, Sweden
¶ Membership in The Swedish Schizophrenia Consortium is listed in the Acknowledgments.
* jin_szatkiewicz@med.unc.edu
Abstract
Copy number variants (CNVs) play an important role in the etiology of many diseases such
as cancers and psychiatric disorders. Due to a modest marginal effect size or the rarity of
the CNVs, collapsing rare CNVs together and collectively evaluating their effect serves as a
key approach to evaluating the collective effect of rare CNVs on disease risk. While a pleth-
ora of powerful collapsing methods are available for sequence variants (e.g., SNPs) in asso-
ciation analysis, these methods cannot be directly applied to rare CNVs due to the CNV-
specific challenges, i.e., the multi-faceted nature of CNV polymorphisms (e.g., CNVs vary
in size, type, dosage, and details of gene disruption), and etiological heterogeneity (e.g.,
heterogeneous effects of duplications and deletions that occur within a locus or in different
loci). Existing CNV collapsing analysis methods (a.k.a. the burden test) tend to have subop-
timal performance due to the fact that these methods often ignore heterogeneity and evalu-
ate only the marginal effects of a CNV feature. We introduce CCRET, a random effects test
for collapsing rare CNVs when searching for disease associations. CCRET is applicable to
variants measured on a multi-categorical scale, collectively modeling the effects of multiple
CNV features, and is robust to etiological heterogeneity. Multiple confounders can be simul-
taneously corrected. To evaluate the performance of CCRET, we conducted extensive
simulations and analyzed large-scale schizophrenia datasets. We show that CCRET has
powerful and robust performance under multiple types of etiological heterogeneity, and has
performance comparable to or better than existing methods when there is no heterogeneity.
Author Summary
Copy number variants (CNVs) are the gain or loss of DNA segments in the genome that
can vary in dosage, length and details of gene disruptions. Rare CNVs have been shown to
be associated with neuropsychiatric disorders both collectively and at specific loci. To eval-
uate the collective effects of rare CNVs on disease risk, sophisticated association methods
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are needed to pool information across CNV loci while handling CNV-specific properties;
however, such methods are under-developed. To address these challenges, we have devel-
oped a new collapsing method for rare CNVs named CCRET. CCRET is a random effects
approach applicable to variants measured on a multi-categorical scale, collectively model-
ing the effects of multiple CNV features, and is robust to etiological heterogeneity. Multi-
ple confounders can be simultaneously corrected. To evaluate the performance of CCRET,
we conducted extensive simulation and analyzed large-scale schizophrenia datasets. We
demonstrate the robustness, validity and utility of CCRET under a variety of scenarios.
Introduction
Copy-number variants (CNVs), such as deletions and duplications, are changes in the number
of DNA copies (in comparison to the reference) and are a major source of genetic variation in
the human genome [1–3]. While a sequence variant (e.g., a SNP) affects a single nucleotide, a
CNV affects a region> 1 Kb. CNV may alter the “dosage” of one or more genes or regulatory
regions in the deleted or duplicated region, which can consequently exert a profound effect on
the risk for human disease. Genomic evaluation of CNVs has established a role for rare (<1%)
CNVs in the etiology of psychiatric disorders, such as schizophrenia, bipolar, and autism [4–
6]. Eight rare CNVs of strong effects are now established risk factors for psychiatric disorders
(e.g., 16p11.2, 22q11.2, genotypic relative risk 4–20) [4, 5]. However, the bulk of CNVs’ contri-
bution to disease risk remains unknown due to a modest effect size or the rarity of the CNV.
As psychiatric disorders are polygenic, collapsing methods [7], which collapse multiple variants
into a group and evaluate their collective effect on disease risk, serve as key approaches to the
analysis of rare CNVs [4, 5]. By accumulating information across multiple rare variants (e.g.,
counting the number of mutations for each individual), collapsing methods can have an
enhanced power to detect genetic variants that are hard to detect individually but collectively
show a significant impact. For example, multiple studies have confirmed a greater genomewide
burden of rare CNVs in schizophrenia cases compared with controls [8–12]. Enrichment anal-
yses of genes impacted by rare CNVs implicated several biological pathways important to
schizophrenia, including those previously associated with schizophrenia through common var-
iation and exome sequencing (e.g., calcium channel signaling and binding partners of the frag-
ile X mental retardation protein) [12].
For rare sequence variants such as SNPs, a plethora of powerful methods are available to
perform collapsing analysis. Depending on the approaches used to model genetic effects and
the procedures used to collapse the information across loci, these methods can be classified
into two major categories: fixed effects methods (e.g., CMC [13], VT [14]) and random effects
methods (e.g., C-alpha [15], SKAT [16], SimReg [17, 18]). A detailed review can be found in
Pongpanich et al. [19] and Lee et al. [20]. Briefly, fixed effects methods collapse information at
genotype level and assess the mean level of the genetic effects via fixed effects modeling; it is
the optimal approach if the effects of different loci are additive and of a similar size. In contrast,
random effects methods collapse information at similarity level and assess the variance level of
the genetic effects via random effects modeling. Random effects methods are more powerful
than fixed effects methods when the variants have different effects (e.g., mixture of positive,
negative and neutral effects).
However, SNP collapsing methods cannot be straightforwardly applied to CNVs due to sev-
eral CNV-specific challenges. First, copy number is measured on a multi-categorical scale (e.g.,
duplication, normal copy and deletion) while SNP collapsing methods assume binary events
CCRET
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(e.g., mutation vs. no mutation). Second, CNV can vary in dosage (i.e., the copy number of a
CNV), length (i.e., the segment size of a CNV) and details of gene disruptions (i.e., the number
of genes that a CNV intersects), and each of these “features” affects CNVs’ impact on disease
risk. For example, in schizophrenia, deletions were enriched in cases to a greater extent than
duplications, and the largest CNVs (> 500 kb) were enriched in cases to a greater extent than
other size categories [8–12]. Girirajan et al. [21] found that the total duplication length is sig-
nificantly elevated in autism cases compared with controls. On the other hand, SNP collapsing
methods target only one feature (i.e., mutation burden). Third, etiological heterogeneity is
often observed in CNVs. While SNPs only exhibit between-locus heterogeneity, the etiological
heterogeneity of CNVs can occur both between loci (e.g., CNVs across different loci have dif-
ferent effects on disease risk) and within a locus (i.e. different dosages of CNV alleles within
the same locus have different effects). (Please see “Input data format” in the Method Section
for detailed definitions of “locus”.) For example, the 22q11.2 deletion is a known risk factor for
schizophrenia [4, 5, 22–24], whereas the reciprocal 22q11.2 duplication is potentially a protec-
tive factor [25]. Microduplications of gene VIPR2 increase the risk for schizophrenia, where
both tandem duplication (copy number 3) and triplication (copy number 4) were observed
with triplication potentially conveying higher risk than duplication [26]. The etiological hetero-
geneity may occur more frequently as CNV detection technologies continue to improve, allow-
ing the accurate detection of small CNVs. Naïve collapsing of a mixture of neutral, risk, and
protective variants between loci or within a locus can cancel signals and lead to power loss.
Random effects SNP-collapsing methods have the potential to address between-locus etiologi-
cal heterogeneity in CNV analyses; however, because these methods record the genetic infor-
mation using the number of mutant events, they cannot deal with the within-locus etiological
heterogeneity observed in multi-categorical scale CNVs.
Collapsing methods based on fixed effects approaches have been developed for rare CNVs
[9, 27]. Specifically, burden-style tests [9] examine CNV events to evaluate whether an
increased rate or the size of the CNVs increases disease risk. Rare CNVs are typically aggre-
gated based on a certain event of interest and then summarized by the event counts, such as the
number of deletions (copy number<2), the number of duplications (copy number>2), the
number of CNVs (copy number 6¼2), or the number of genes intersected by the CNVs. The
association is evaluated by comparing the event rates between cases and controls. However,
this approach falls short in three aspects. First, the researcher must pre-select a CNV event
(e.g., deletion or duplication or both) and summarize the data using the appropriate event
counts. Second, it ignores etiological heterogeneity. Finally, it only evaluates the marginal
effects of a CNV feature, which may or may not be a valid approach depending on the collaps-
ing unit. For example, while the gene-count burden test is valid for a genomewide collapsing, it
can result in spurious association if based on a gene set [27]. To address the last issue, enrich-
ment-style tests [27] have been proposed to assess the conditional effect of a CNV feature; such
a test compares the counts of genes within a pre-specified gene set intersected by CNVs in
cases with the counts in controls while controlling for case-control differences in genomewide
CNV rate and size. Although it uses a joint modeling to avoid spurious association, this method
does not address the issue of etiological heterogeneity and still needs to summarize CNV data
into counts based on the feature of interest.
We have developed a new collapsing method for the analysis of rare CNVs that is applicable
to variants measured on a multi-categorical scale, collectively modeling the effects of multiple
CNV features, and is robust to etiological heterogeneity. Our method is called CCRET (CNV
Collapsing Random Effects Test, pronounced as “se-cret”). Specifically, we use random effects
to model the CNV effect of interest, which, for SNP collapsing analysis, has been shown to
be more robust than a fixed effects approach when the complexity of genetic architecture
CCRET
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increases [19, 20]. When aggregating information through CNV similarity, we define “locus”
units for each CNV feature to retain the “locus”-specific effect during collapsing, and use fac-
torized design vectors for multi-categorical CNV features to quantify similarity without dichot-
omizing the data as is done in the fixed effects methods. CCRET can simultaneously correct for
covariates such as batch effects and population substructures. CCRET can be viewed as an
extension of the SNP-set random effects methods (e.g., C-alpha [15], SKAT [16], SimReg [17,
18]) applicable to CNV data. To evaluate the performance of CCRET, we conducted extensive
simulations under various scenarios and analyzed large-scale CNV data from the Swedish
schizophrenia study. Our results suggest that, compared with the existing (fixed effects) CNV
collapsing methods implemented in PLINK [9, 27, 28], our random effects approach has a sta-
ble, powerful and robust performance under multiple types of etiological heterogeneity, and
has a comparable or better performance when there is no heterogeneity.
Results
Overview of CCRET (CNV Collapsing Random Effects Test)
Fig 1 provides an overview of the CCRET method using the dosage effects model as an exam-
ple. CCRET aims to detect any association of the aggregated CNV effect with disease risk and
has the following key features. First, CCRET converts the source CNV data to three input
matrixes in order to store the different features of CNVs, i.e., dosage (“DS”), length (“Len”),
and gene intersection (“GI”). For “DS” and “Len”matrixes, we use CNV regions as the “locus”
unit. For “GI”matrix, we use genes as the “locus” units. Second, CCRET models the covariates
and background CNV features using fixed effects as did in Raychaudhuri et al [27], and models
the CNV feature of interest using random effects in order to retain the locus-specific details
and to account for both between-locus and within-locus etiological heterogeneity. Third,
CCRET quantifies the genetic similarity between any two individuals based on the CNV feature
of interest, which is then used to depict the covariance among the CNV effects of different indi-
viduals (i.e, the more similar the genetic feature between two individuals is, the more correlated
their CNV effects would be). When calculating genetic similarity, we factorize the multi-cate-
gorical allele values recorded in the input matrices. Consequently, alleles with opposite effects
within a locus are not lumped together when computing similarity, which makes CCRET
robust against within-locus heterogeneity. In contrast, SNP-collapsing random effects methods
(e.g., C-alpha [15], SKAT [16], SimReg [17, 18]) do not address within-locus heterogeneity.
Finally, under the mixed effects model framework, the aggregate CNV effect can be evaluated
by examining the significance of the variance component. In contrast, fixed effects methods
test the aggregated CNV effect by examining if the common (e.g., averaged) effect is equal to
zero.
Fig 2 provides an overview of the evaluative analyses carried out in this work. We conducted
two sets of simulations under a variety of scenarios and conducted real data analysis using
large-scale schizophrenia datasets. We evaluated the performance of CCRET in comparison to
the fixed effects CNV-collapsing methods implemented in PLINK [9, 27, 28].
Simulation studies for performance evaluations
We conducted two sets of simulations to evaluate the performance of our method under a vari-
ety of scenarios: (I) causal dosage effects and (II) causal gene intersection (GI) effects. In each
simulation, the genotypes of rare CNVs were taken from the TwinGene study [29, 30], which
used a cross-sectional sampling design and selected 6,611 unrelated subjects born between
1911 and 1958 from the Swedish Twin Registry [31–33] (STR) for genomic characterization.
These samples included one member per monozygotic twin pair and a randomly selected
CCRET
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member per dizygotic twin pair. DNA was extracted from peripheral venous blood for all sub-
jects. The samples were genotyped on the Illumina OmniExpress beadchip for 72,881 SNP
markers using standard protocol; CNV calling was performed using PennCNV [34] (version
Fig 1. An overview of the CCRETmethod. The dosage effects model was used as an example. C1-4: cases, N1-4: controls, CNVR: copy number variation
region, red rectangle: deletion, blue rectangle: duplication, green rectangle: gene. DS: dosage, Len: length, GI: gene intersection.
doi:10.1371/journal.pgen.1005403.g001
CCRET
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June 2011) with recommended model parameters. We randomly selected 2,000 subjects from
the TwinGene study and formed 1,757 CNV regions (CNVRs) genome-wide with frequency
<1%. The detailed data processing procedure is described in S1 Text. In each simulation set-
ting, we used case-control sampling to collect 2,000 cases and 2,000 controls, evaluated the
type I error rates based on 2,000 replications and evaluated the power based on 300
replications.
Simulation I: evaluating dosage effects. We considered causal dosage effects with two
types of etiological heterogeneity between deletions and duplications: (A) between-locus
heterogeneity, and (B) within-locus heterogeneity. We simulated the binary phenotype of









m  zDS:Delim , where zDS:Dupim ¼ 1 if individual i at
causal locusm has a duplication and 0 otherwise; zDS:Delim is defined in a similar fashion for dele-
tion events; bDS:Dupm and b
DS:Del
m are the log of the odds ratios (ORs) of causal locusm for duplica-
tions and deletions, respectively; bDS:Dupm and b
DS:Del
m shared the same absolute values for all
causal loci but were positive if associated with increased disease risk and negative if protective
effects. We compared CCRET to the collapsing methods implemented in PLINK. Specifically,
PLINK command “—cnv-indiv-perm” was applied to duplications only (referred to as PLINK.
dup), deletions only (referred to as PLINK.del), and deletions and duplications combined
(referred to as PLINK.all). The PLINK p-values were computed using 10,000 permutations.
Simulation I-A: between-locus heterogeneity of the dosage simulation. Among the
1,757 CNVRs, there are 766 loci with duplication genotypes only (dosage 3 or 4, “DupOnly”
hereafter), 840 loci with deletion genotypes only (dosage 0 or 1, “DelOnly” hereafter), and 151
loci with both deletion and duplication genotypes (dosage 0,1,3,4, “DupDel” hereafter). We
considered 600 causal loci where 300 loci were randomly selected from the 766 DupOnly loci
and 300 loci were randomly from the 840 DelOnly loci. We considered 6 heterogeneity models
with different proportions of risk-associated (bDS:m > 0) or protective (b
DS:
m < 0) effects among
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causal loci. The first three served as the baseline models which favor the PLINK burden tests,
i.e., (1) all DupOnly risk-associated and all DelOnly protective (i.e., βDS.Dup +/− = 100/0 and
βDS.Del +/− = 0/100); (2) all DupOnly protective and all DelOnly risk-associated (i.e., βDS.Dup
+/− = 0/100 and βDS.Del +/− = 100/0); (3) all causal loci risk-associated (i.e., no heterogeneity)
with βDS.Dup +/− = 100/0 and βDS.Del +/− = 100/0. The remaining three models consider differ-
ent levels of heterogeneity, i.e., (4) βDS.Dup +/− = 70/30 and βDS.Del +/− = 30/70; (5) βDS.Dup +/−
= 30/70 and βDS.Del +/− = 70/30, and (6) βDS.Dup +/− = 50/50 and βDS.Del +/− = 50/50. For each
scenario, we assumed a constant OR for casual loci and considered OR ranging between 1 and
7, chosen based on the empirical evidence of pathogenic CNVs in psychiatric disorders [4, 5].
The type I error rates were around the nominal level for all methods under between-locus,
although the results of CCRET are slightly conservative (Table 1). For power analyses, we first
compared CCRET to PLINK 1-sided tests, which assess whether the event rate is higher in
cases than in controls (Fig 3). In models (1) to (3) (Fig 3 upper panel, where duplications (dele-
tions) have the same effects and PLINK tests would be the most powerful), CCRET provided
comparable power to the best PLINK methods while the best PLINK method varied. Specifi-
cally, in (1) where all duplications were risk-associated and all deletions were protective,
PLINK.dup was the best method as expected; similarly, in (2), PLINK.del was the best method
as expected; and in (3), PLINK.all was the best method, because PLINK.all used all available
information whereas PLINK.dup or PLINK.del only used a subset of the total events. In Models
(4) to (6), (Fig 3 lower panel, where different combinations existed of risk-associated and pro-
tective effects in βDup and βDel), CCRET consistently yielded the best power or yielded power
comparable to the best PLINK method. From Fig 3, we also see that the performance of PLINK
1-sided tests was highly dependent on the underlying effect mechanisms. Specifically, the best
PLINK 1-sided tests were those focused on the CNV events with risk-associated effect, and
those PLINK 1-sided tests that focused on the events with protective effects had no power. In
the presence of etiological heterogeneity (i.e., Models (1), (2), and (4) through (6)), the perfor-
mance of PLINK.all was hard to predict; roughly speaking, it tended to be in and between
PLINK.dup and PLINK.del, and the power somewhat depended on the relative proportion of
the causal risk-associated and causal protective CNVRs.
In Fig 4, we compare CCRET to PLINK 2-sided tests. For PLINK 2-sided tests, we observed
a pattern of the relative performance of PLINK and CCRET similar to that seen in Fig 3. The
only exception was that PLINK.dup and PLINK.del had good power under heterogeneity mod-
els (1) and (2). In sum, PLINK 2-sided tests are more robust than PLINK 1-sided tests when
the underlying effect patterns are unknown; and therefore we present the comparisons of
CCRET and PLINK 2-sided tests for the remaining simulation studies.
Simulation I-B: within-locus heterogeneity of the dosage simulation. We selected 38
loci out of the 151 DupDel loci to be causal and the selected causal loci tended to have a similar
number of duplications and deletions. We considered 5 heterogeneity models, where deletions
and duplications had different combinations of risk-associated (R), protective (P) or neutral
Table 1. Type I error rates for evaluating dosage effects (nominal alpha = 0.05).
Model CCRET PLINK.all PLINK.dup PLINK.del
(A) Between-locus heterogeneity 0.035 0.046* 0.057 0.041
(0.047)** (0.053) (0.055)
(B) Within-locus heterogeneity 0.041 0.051 0.057 0.043
*: Type I error rates based on PLINK 2-sided tests
**: Type I error rates in parentheses are based on PLINK 1-sided tests.
doi:10.1371/journal.pgen.1005403.t001
CCRET
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(N) effects on the phenotypes. Specifically, the five effect combinations considered were (Dup,
Del) = (R,N), (N,R), (P,R), (R,P) and (R,R) (i.e., no heterogeneity). For example, “(Dup, Del) =
(P,R)” indicates that, within each of the 38 loci, duplications had protective effects, whereas
deletions had risk-associated effects. For each model, we set a constant OR for the casual loci
and considered OR ranging between 1 and 20, chosen based on empirical evidences [4, 5].
Table 1 shows that the type I error rates were around the nominal level for all methods. The
power results (Fig 5) show that CCRET had power comparable to or better than the best
PLINK test across all heterogeneity models considered. Again, the best PLINK test varied
across heterogeneity models, but overall it focused on the CNV allele with risk-associated
effects. The PLINK tests that focused on the protective (neutral) alleles had low (no) power.
PLINK.all had power similar to and between PLINK.dup and PLINK.del, except in the case
where within-locus heterogeneity did not exist, i.e., (R,R).
Simulation II: evaluating GI effects. In Simulation II, we considered causal GI with het-
erogeneous effects between a duplication GI and deletion GI. In the TwinGene data, we focused
on 668 protein-coding genes in the neuronal postsynaptic density (PSD) because previous
researchers have reported enrichment of rare CNVs in the PSD genes in schizophrenia cases
[12, 35]. CNVs intersected 69 of the 668 genes, where 35 genes were intersected by duplications
Fig 3. Power comparison between CCRET and PLINK 1-sided tests for simulation I-A: between-locus heterogeneity of the dosage simulation. As
detailed in section “Simulation Design”, we considered 6 heterogeneity models with different proportions of risk-associated (bDS:m > 0) or protective (b
DS:
m < 0)
effects among causal loci. BlackO line: CCRET; Blue Δ: PLINK 1-sided test analyzing deletions and duplications combined; Green +: PLINK 1-sided test
analyzing only duplications; Magenta x: PLINK 1-sided test analyzing only deletions.
doi:10.1371/journal.pgen.1005403.g003
CCRET
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only (“DupOnly genes” hereafter), 26 genes were intersected by deletions only (“DelOnly
genes” hereafter), and 8 genes were intersected by both deletions and duplications (“DupDel
genes” hereafter). Similar to the first simulation study, we considered (A) between-gene
heterogeneity and (B) within-gene heterogeneity. We simulated the binary phenotype of









m  zGI:Delim þ bCNV  zCNV ;i þ bLen  zLen;i,
where zGI:Dupim ¼ 1 if causal genem is intersected by a duplication and 0 otherwise; zGI:Delim is
defined similarly for deletion; zCNV,i is the total number of CNV events; and, zLen,i is the mean
size of the CNVs measured in kb. The regression coefficients bGI:Dupm and b
GI:Del
m are the log
(OR)’s of causal genem for a duplication intersection and a deletion intersection, respectively;
bGI:Dupm and b
GI:Del
m shared the same absolute values for all causal loci but were positive if risk-
associated effects and negative if protective effects; βCNV and βLen were set to be log(1.5). We
compared CCRET with the PLINK enrichment test as described in Raychaudhuri et al. [27].
We implemented the procedure in R and reported the 2-sided asymptotic p-values as done in
the default option of PLINK “—cnv-enrichment-test”. We performed the enrichment analysis
for deletions and duplications combined (referred to as PLINK.enrich), deletions only (PLINK.
enrich.del), and duplications only (PLINK.enrich.dup).
Fig 4. Power comparison between CCRET and PLINK 2-sided tests for simulation I-A: between-locus heterogeneity of the dosage simulation,
under 6 heterogeneity models as in Fig 3. BlackO line: CCRET; Blue Δ: PLINK 2-sided test analyzing deletions and duplications combined; Green +:
PLINK 2-sided test analyzing only duplications; Magenta x: PLINK 2-sided test analyzing only deletions.
doi:10.1371/journal.pgen.1005403.g004
CCRET
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Simulation II-A: between-locus heterogeneity of the GI simulation. We randomly
selected 26 genes from the DupOnly genes and 26 genes from the DelOnly genes, and used the
52 genes as causal loci. We considered 6 heterogeneity models similar to the models considered
in the dosage simulation: (1) DupOnly risk-associated and DelOnly protective (i.e., βGI.Dup +/−
= 100/0 and βGI.Del +/− = 0/100); (2) DupOnly protective and DelOnly risk-associated (i.e., βGI.
Dup +/− = 0/100 and βGI.Del +/− = 100/0); (3) all causal loci risk-associated (i.e., no heterogene-
ity with βGI.Dup +/− = 100/0 and βGI.Del +/− = 100/0); (4) βGI.Dup +/− = 70/30 and βGI.Del +/− =
30/70; (5) βGI.Dup +/− = 30/70 and βGI.Del +/− = 70/30; and (6) βGI.Dup +/− = 50/50 and βGI.Del
+/− = 50/50. We set a constant effect size for all casual loci and considered the OR ranging
between 1 and 20, chosen based on empirical evidences [4, 5].
Table 2 shows that the type I error rates were around the nominal level for PLINK.enrich
and CCRET, although CCRET was slightly conservative. Fig 6 suggests a consistent power gain
Fig 5. Power comparison between CCRET and PLINK 2-sided tests for simulation I-B: within-locus heterogeneity of the dosage simulation, under
5 heterogeneity models as detailed in section “Simulation Design”. BlackO line: CCRET; Blue Δ: PLINK 2-sided test analyzing deletions and
duplications combined; Green +: PLINK 2-sided test analyzing only duplications; Magenta x: PLINK 2-sided test analyzing only deletions.
doi:10.1371/journal.pgen.1005403.g005
Table 2. Type I error rates for evaluating GI effects (nominal alpha = 0.05).
Model CCRET PLINKenrich PLINK enrich.dup PLINK enrich.del
(A) Between-locus heterogeneity 0.041 0.044 0.051 0.042
(B) Within-locus heterogeneity 0.043 0.051 0.052 0.043
doi:10.1371/journal.pgen.1005403.t002
CCRET
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of CCRET over PLINK.enrich, PLINK.enrich.dup and PLINK.enrich.del across all heterogene-
ity models. The consistent power gain in CCRET, which was not observed in the dosage simu-
lation, was perhaps because the signal to noise ratio (SNR) in the GI simulation was smaller
than that in the dosage simulation. Specifically, the SNR was 7.8% for this simulation but
34.1% in the dosage simulation. In SNP analysis, it has also been found that fixed effects
approaches tend to be less powerful than random effects approaches when a high proportion
of non-causal loci exist [19, 20]. Among the PLINK methods, PLINK-del has the lowest power
in most of the scenarios, which is likely because in the causal genes, there are more duplication
events intersecting the DupOnly causal genes than deletion events intersecting the DelOnly
causal genes.
Simulation II-B: within-locus heterogeneity of the GI simulation. We used the 6 “Dup-
Del” genes as causal and considered 3 heterogeneity models, i.e., (Dup, Del) = (P,R), (R,P) and
(R,R) (no heterogeneity). We set a constant effect size for all casual loci and considered OR
ranging between 3 and 50, chosen based on empirical evidences [4, 5]. The type I error rates
(Table 2) were around the nominal level for PLINK.enrich methods and CCRET. The power
results (Fig 7) suggest a consistent power gain of CCRET over PLINK.enrich based methods.
The SNR was 1.2% for II-B and 2.2% in the I-B dosage simulation. In Fig 7, PLINK.del had the
Fig 6. Power comparison between CCRET and PLINK 2-sided tests for simulation II-A: between-locus heterogeneity of the GI simulation, under 6
heterogeneity models as detailed in section “Simulation Design”. BlackO line: CCRET; BlueΔ: PLINK 2-sided test analyzing deletions and duplications
combined; Green +: PLINK 2-sided test analyzing only duplications; Magenta x: PLINK 2-sided test analyzing only deletions.
doi:10.1371/journal.pgen.1005403.g006
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highest power among PLINK tests since, among the 8 DupDel causal genes, there were more
deletions than duplications. Note that we used the same aggregate functions as PLINK.enrich
to model the background CNVs (i.e., dosage and size) in CCRET’s GI model. Therefore the
CCRET’s GI model was the same as the PLINK.enrich model except the GI effect was modeled
using a random effect. Consequently, the power gain in CCRET can be attributed to the use of
random effects modeling of the GI effect.
Data application
We applied CCRET to CNV data from the Swedish schizophrenia study [36] and compared its
performance to that of PLINK. The Swedish schizophrenia study used a case-control sampling
design. Genotyping was done in six batches (Sw1-6) at the Broad Institute using Affymetrix 5.0
(3.9%, Sw1), Affymetrix 6.0 (38.6%, Sw2-4), and Illumina OmniExpress (57.4%, Sw5-6). We
applied PennCNV [34] to generate CNV calls using the same protocol as we did for samples
from the TwinGene project. After stringent quality control, we obtained a high-quality rare
CNV (frequency<1%, size>100 Kb) dataset in 8,547 subjects (3,637 cases with schizophrenia
and 4,820 controls) [36]. Further details on quality control can be found in S1 Text. Previous
analyses of this data indicated significant associations of large rare CNVs with schizophrenia
risk for both genomewide dosage effects and GI effects of selected gene sets; and the associa-
tions were stronger when restricting to the largest categories (e.g. size> 500 kb) [9, 12]. CNVs
with size>500 kb may be relatively more homogenous than CNVs with size> 100kb in the
effects on disease risk as more causal genes may be impacted [9, 12].
We obtained the CNV data in PLINK format and converted it to the CCRET-format
matrixes (“DS”, “Len”, “GI”). We verified that they stored identical information (i.e., the same
total CNV numbers, average CNV lengths, and counts of intersected genes for each individual).
We used the polynomial kernel with d = 1 and fit CCRET models (2) and (4) to evaluate the
dosage effects and GI effects, respectively. The CCRET p-values were obtained using the Davies
method [37]. We started by examining CNVs of size greater than 100kb, using CCRET and the
2-sided PLINK methods; and then repeated the analysis using CNVs of size greater than
500kb. In all analyses, we adjusted for the batch effect by including a batch indicator [9, 12]. As
each genotyping batch used one specific type of arrays, controlling for genotyping batch effect
Fig 7. Power comparison between CCRET and PLINK 2-sided tests for simulation II-B: within-locus heterogeneity of the GI simulation, under 3
heterogeneity models as detailed in section “Simulation Design”. BlackO line: CCRET; BlueΔ: PLINK 2-sided test analyzing deletions and duplications
combined; Green +: PLINK 2-sided test analyzing only duplications; Magenta x: PLINK 2-sided test analyzing only deletions.
doi:10.1371/journal.pgen.1005403.g007
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simultaneously controlled for the difference in genotyping array. The comparison results are
summarized in Table 3 for dosage effects and Table 4 for GI effects.
For dosage effects with CNVs that are>100kb, the results of PLINK.all and CCRET are dif-
ferent: PLINK.all (p-value 0.597) suggested no signal while CCRET had a significant p-value of
0.002. When focusing on CNVs that are>500kb, we replicated the literature finding of a signif-
icant association [9, 12] using both PLINK and CCRET: the p-value of PLINK.all is significant
(p-value 0.013) while the p-value of CCRET is comparable (p-value 0.031). It seems that CNVs
with size>500kb have relatively homogeneous dosage effects on the schizophrenia risk, where
the case/control ratios of CNV rate are in the same directions for deletions-only and duplica-
tions-only (both>1.1, indicating an excess burden in cases). On the other hand, CNVs with
size>100kb could have heterogeneous dosage effects, where the case/control ratios of CNV
rate are in different directions for deletions-only (>1) and duplications-only (1). Conse-
quently, PLINK.all had a significant result with>500kb CNVs but insignificant results with
>100kb. In contrast, CCRET, due to its robustness with respect to the heterogeneity, yielded
significant p-values for both types of CNVs. The results are not unexpected based on our find-
ings in the simulations, where we observed that when CNVs have relatively homogeneous
effects (which may occur in the case of CNVs>500kb in the real data), the best PLINK method
can be more powerful than CCRET; when CNVs have heterogeneous effects (which may occur
in the case of CNVs>100kb in the real data), CCRET is more powerful than PLINK.
For GI effects, we analyzed nine gene sets where significant enrichments of large rare CNVs
in schizophrenia cases have been previously reported [12]. Further details on these gene sets
can be found in S1 Text. For most gene sets except for PSD-95, a similar pattern was observed
with the GI analysis as with the dosage analysis: With CNVs> 500kb, we replicated the literature
finding of significant associations [12] using both PLINK.enrich and CCRET. With CNVs>
100kb, we obtained different results between PLINK.enrich and CCRET,where CCRET often
yielded significant p-values while PLINK.enrich did not. These results are not unexpected based
on our findings in the simulations. For PSD-95, we observed significant results using PLINK.
enrich for both CNVs> 100kb and CNVs> 500kb but insignificant results using CCRET.
These results perhaps were influenced by the potentially high signal-to-noise-ratio in this small
gene set (i.e. high proportion of causal loci) and relatively more homogenous CNV effects, which
favors fixed effects collapsing methods over random effects methods.






























DUP 5070 0.599 0.600 0.997 1383 0.966




840 0.110 0.091 1.199 300 202
(67%)
57 (19%) 41 (14%) 0.013 0.031
DUP 617 0.080 0.068 1.175 246 0.062
DEL 223 0.030 0.024 1.267 99 0.085
DUP: duplications. DEL: deletions. Case (or control) CNV rate = the total number of CNVs in cases (or controls) divided by the total number of cases (or
controls). Case/control ratio = Case CNV rate divided by control CNV rate. CNVR: copy number variation region. Pval_PLINK: 2-sided p-values based on
10,000 permutations and permuting phenotype labels within genotyping batches (asymptotic p-values were similar). Pval_CCRET: 2-sided p-values based
on the Davies (1980) method.
doi:10.1371/journal.pgen.1005403.t003
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Discussion
CNVs play an important role in disease etiology [4, 5]. While it is more informative to examine
CNVs in the aggregate due to sparse events or modest marginal effects, current polygenic
methods are mainly designed for bi-allelic SNPs and do not fully address the CNV-specific
challenges. The challenges include the multiple features of a CNV affecting phenotypes, the
non-biallelic nature of CNV polymorphisms, and etiological heterogeneity within and between
loci. In this work, we introduce CCRET, a random effects method for CNV collapsing analysis
that accommodates the poly-allelic nature of CNVs, models multiple CNV features and
accounts for etiological heterogeneity. Simulation and real data analyses suggest that CCRET
has stable performance across different scenarios of heterogeneity, and has a comparable or
better power when compared to PLINK collapsing methods. The largest power gain tends to
occur when heterogeneity pattern are complex, e.g., a mixture of risk-associated and protective
effects observed within a locus or within a certain CNV type (duplication or deletion). The
average running time for performing CCRET analysis with 4000 individuals is 27.5 seconds on
an Intel Xeon 3.06 GHz machine with 64 Gb RAM.
With CCRET, we address the etiological heterogeneity by retaining the “locus”-specific
effects and “allele”-specific effects during collapsing. To retain the locus-specific effect during
collapsing, we define a locus unit for each CNV feature (e.g., CNVRs for dosage and genes for
gene intersection); based on the locus definition, we quantify similarity shared between an indi-
vidual pair for each locus and then aggregate the similarity information across loci. Because the
multi-locus information is aggregated through a sum of genotype similarity instead of a sum of
genotypes, loci with opposite effects do not cancel each other out. To retain allele-specific effect
during collapsing, we factorize the allele values recorded in the design matrixes before calculat-
ing similarity. Factorizing the allele values avoids the need of dichotomizing the polymor-
phisms of a CNV feature and gains robustness against within-locus heterogeneity (as alleles
with opposite effects do not need to be lumped together).
For GI analysis, we use genes instead of CNVRs as the locus unit. If CNVRs are used, the
entry of the design matrix would record the number of genes intercepted by a certain CNV in
the CNVR. Such data scoring may not be ideal when different intersected genes have different
etiological effects. Hence we use genes as the locus unit so that the entry of the design matrix
records the type of CNVs intersecting a gene. This allows us to model the gene-specific effects
as well as the effects of the specific CNV type that intersects the gene.
Currently, there is no clear consensus on how to define CNVRs. One typical definition of
CNVR is based on forming clusters of individual segments with some arbitrary amount of
overlapping (e.g., 1 base pair overlap, 50% reciprocal overlap), and then allele frequency is
computed for each CNVR. The choice of overlapping threshold could impact the formation of
heterogeneous clusters that contain segments of variable sizes and breakpoints, each of which
only overlap by a few base pairs but which may be disease relevant. For example, rare NRXN1
deletions are associated with schizophrenia and show variable breakpoints and lengths among
schizophrenia cases [38]. Such heterogeneous clusters of rare CNVs can occur frequently with
high-resolution CNV detection technologies (e.g., high-density microarray and high-through-
put sequencing); therefore defining CNVRs requires care [1, 4, 5]. In this work, we used the
most inclusive threshold of 1 base-pair overlap to define CNVRs. Future study could account
for CNVRs overlapping pattern by including them as fixed-effect covariates.
The simulation analyses show that, while sensitive to the underlying effect mechanism, the
best PLINK (fixed effects) tests can be more powerful than CCRET when the effects of CNVs
are homogeneous (such as the effects of>500kb CNVs in the real data analysis). The results
agree with the findings in the SNP collapsing analysis; that is, the fixed effects approaches,
CCRET
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which use the total event count to summarize the variant information within the target region,
are the optimal methods when the majority of the variants in the region affect the phenotype in
the same direction and with similar magnitude. On the other hand, when there exist non-
causal variants (e.g., the effects of>100kb CNVs in the real data analysis) or a mixture of risk-
associated and protective variants, random effects approaches are optimal because of their abil-
ity to account for effect heterogeneity. Taking together, we recommend that researchers apply
both PLINK (fixed effects) and CCRET (random effects) in real-world rare CNV analysis
because the underlying mechanisms of genetic effects are typically unknown.
Further, one future direction in which CCRET could be improved is to consider a hybrid
approach, such as the SKAT-O test for rare SNP analysis [39]. Such a hybrid approach can
retain the robustness of the random effects approach while retaining the test power of the fixed
effects approach when the CNVs have homogeneous effects.
In the current work, we modeled the CNV feature of interest using random effects and the
background CNV features using fixed effects. Alternatively, one can use random effects to
model all CNV features; under this “fully random effects”model, the overall effect of each
CNV feature is captured by a variance component. However, the calculation of the test statis-
tics can be extremely computationally intensive, especially with large samples and non-normal
traits, because it involves estimating several nuisance variance components. Similar computa-
tional concerns have also been encountered in GLMM based approaches for gene-environment
interactions [40, 41]. We are exploring possible low-rank approximations to the CNV kernel
matrixes using kernel principal component analysis [42] to reduce the computational burden
in a fully random effects model.
To date, significant associations of rare CNVs with psychiatric disorders have been
limited to the largest CNVs (e.g.>500 kb) [1, 4, 5]. In this work, the significant results with
CNVs> 100kb obtained by CCRET are intriguing. There have been increasing evidences
that smaller CNVs may contribute to the risk of psychiatric disorders [43, 44], although such
associations have been challenging to detect because analytic methods are under developed.
Improvement in CNV detection technologies will increase our ability to detect smaller CNVs
(e.g.,<20 kb), for which etiological heterogeneity can be more frequently encountered. The
CCRET method could be important in analyzing smaller CNVs given its robustness in a variety
of heterogeneous scenarios.
As we move ahead, success will increasingly depend on our ability to integrate all classes of
genetic variation into a more complete disease model, including joint analysis of SNPs and
CNVs [45]. For example, in schizophrenia genetics, multiple lines of genomic inquiry–
genome-wide screens for rare CNVs, common SNPs, and rare exonic variation–are converging
on similar sets of pathways and/or genes [12, 35, 36, 46]. The CCRET method may open a door
for joint analysis as various variant types can be incorporated and simultaneously modeled
under a random effects framework.
Materials and Methods
Ethics statement
All procedures were approved by ethical committees at the Karolinska Institutet in Sweden and
at the University of North Carolina at Chapel Hill in the US, and all subjects provided written
informed consent (or legal guardian consent and subject assent).
Input data format
As PLINK (version 1.07) is the standard software for CNV analysis from case/control data, we
assume a PLINK-format CNV file as the source data, which lists the base pair position (start
CCRET
PLOSGenetics | DOI:10.1371/journal.pgen.1005403 October 2, 2015 16 / 24
and end) and copy number (or dosage coded as 0,1,3,4+) of individual CNV segments. We cre-
ate three input matrixes to store the different features of CNVs, i.e., dosage (“DS”), length
(“Len”), and gene intersection (“GI”). For dosage and length matrixes, we first form the CNV
region (CNVR) as the “locus” unit by clustering CNV segments using1bp overlap from the
PLINK format file. The (i,m)-entry of the DS matrix indicates the copy number (0, 1, 2, 3, 4+)
of the CNV segment for subject i at CNVRm, and the (i,m)-entry of the Len matrix indicates
the corresponding segment size in the DS matrix. The use of CNVRs allows us to keep track of
CNVR-specific effects and to account for heterogeneity between and within CNVRs in the col-
lapsing analysis.
For the gene intersection (“GI”) matrix, instead of using CNVRs as we did for dosage and
length, we use genes as the collapsing units to keep track of the effect of different genes when
they are interrupted by CNVs. We obtained the coordinates of the genes of interest (http://
genome.ucsc.edu/), and then create the GI matrix where the (i,m)-entry indicates whether
genem of subject i is intersected (1bp overlapping) by a CNV and the corresponding CNV
type (i.e., 0 for no intersection, 1 for intersection by a deletion, and 2 for intersection by a dupli-
cation). The genes of interest can be a collection of all protein coding genes or a collection of
genes in a specific pathway. Using the gene as the locus unit allows us to evaluate the heteroge-
neous effects between and within genes in specific pathways. Alternatively, an exon could be
used as the observation unit.
CCRET can handle CNVs called from both microarray and sequencing data. CNV files gen-
erated by CNV-calling algorithms from sequencing data are either in the Variant Call Format
(VCF), such as those used by the 1000 Genomes project [3, 47], or in VCF-like but algorithm-
specific output format (e.g., DATA.xcnv produced by the XHMM [48, 49] software from
exome sequencing data). With CCRET, its data preparation pipeline provides scripts to convert
any input CNV files first to PLINK-format CNV files as the source data and then to CCRET-
specific CNV input matrixes (DS, Len, GI) for use in random effects modeling.
CCRETmethod
For subject i, let Yi be a continuous or binary trait, Xi be a p × 1 covariate vector including the
intercept, and Zfi ¼ ½Zfi1;    ;ZfiMf  be aMf × 1 design vector of feature f in a certain genomic
region, e.g., whole genome, pathway or certain type of genes. For f = DS or Len, the design vec-
tor length,Mf, is the number of CNVRs in the targeted genomic region; for f = GI,MGI is the
number of genes in the targeted genomic region.
Suppose Yi follows a distribution from the exponential family with density fY(Yi;θi,ϕ) = exp
[{θiYi − b(θ}/{ϕvi}] + c(yi,ϕ), where θi is the canonical parameter with θi = g(μi) with g() being
a known link function, mi ¼ EðYi jXi;ZDSi ;ZGIi ;ZLeni Þ, b() and c() are known functions, ϕ is a
dispersion parameter, and vi is a known weight. The mean and variance of Yi satisfy μi = b0(θi)
and VðYi jXi;ZDSi ;ZGIi ;ZLeni Þ ¼ v1i b@ðyiÞ where b0 yið Þ ¼ @@yi b yið Þ and b@ yið Þ ¼ @@yi b0 yið Þ. We
posit the following model to study the effects of CNV features on the trait values:
gðmiÞ ¼ g0Xi þ hDSðZDSi Þ þ hGIðZGIi Þ þ hLenðZLeni Þ; ð1Þ
where the covariate effects are modeled with effect size vector g0p1, and hf() with f 2 {DS, GI,
Len} is a smooth function that models the effect of CNV feature f. There are many possible





CNVR to have its own effect βf,m, therefore maximizing its ability to capture heterogeneity.
This model corresponds to a classic linear regression but suffers from low power due to large
degrees of freedom and sparse information. In order to reduce the degrees of freedom, one
CCRET
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may impose a random effects model by assuming that the individual effects follow a normal
distribution βf,m * N(0,τf). Alternatively, Raychaudhuri et al.[27] (PLINK methods) consid-
ered the aggregated functions hDSðZDSi Þ ¼ bDS 
PMDS
m¼1 IfZDSim 6¼ 2g (where
PMDS
m¼1 IfZDSim 6¼ 2g
is the total number of CNVs of subject i) and hGIðZGIi Þ ¼ bGI 
PMGI
m¼1 IfZGIim 6¼ 0g (wherePMGI
m¼1 IfZGIim 6¼ 0g is the number of genes intersected by CNVs for subject i), which nicely
amplify the information content and avoid the problem of dimensionality by testing the aver-
aged/common effect.
With CCRET, to avoid the dimensionality problem, we propose to model the covariates and
background CNV features (measured from whole genome) using fixed effects, such as by set-
ting hf() as those considered in Raychaudhuri et al [27], but to model the CNV feature of inter-
est (measured from the genomic regions of interest) using random effects. Specifically, when
evaluating the effect of CNV feature f, we set hf ðZfi Þ 	 hfi , where hfi represents the subject-spe-
cific effect of multi-locus CNVs with feature f and is assumed to be random. Modeling the tar-
geted CNV feature using random effects can capture the locus-specific details and account for
between-locus and within-locus etiological heterogeneity when collapsing the information
across different CNV regions. Treating the background CNV features as fixed effects can
greatly boost the computational efficiency by bypassing the need to estimate the nuisance vari-
ance components, which can be burdensome with non-normal traits. As in the random effects
approaches for SNP analyses (e.g., C-alpha [15], SKAT [16], SimReg [17, 18]), we assume that
hf ¼ ðhf1;    ; hfn ÞT 
 Nð0; tf Kf Þ where Kf ¼ f Kf ðZfi ;Zfj Þ g
n
i;j¼1 and Kf(,) is a distance metric
that quantifies the similarity between subject i and subject j based on CNV feature f in the tar-
geted genomic region. In other words, the CNV information of feature f in the targeted region
is first summarized by genetic similarity, which is then used to depict the covariance between
CNV effects hfi and h
f
j . The aggregate CNV effect of feature f can be evaluated by examining the
significance of the variance component τf (i.e., testing H0: τf = 0).
CCRET’s connection with other random-effects collapsing methods
The proposed CCRET model has a direct connection with kernel machine regression [16, 50,
51] and gene-trait similarity regression [17, 18] because both kernel machine and similarity
regressions have a mixed model representation. Specifically, under the kernel machine frame-
work, our CCRET model is equivalent to specifying the CNV feature of interest, hf(), through




j  Kf ðZfi ;Zfj Þ with
afj being the unknown parameter (the dual representation), or the equivalent basis representa-




‘  f‘ðZfi Þ, where ff1ðZfi Þ;    ; fLðZfi Þg is a set of the orthogonal basis
functions spanning the functional space specified by Kf(,) and Zf‘ is the unknown parameter.
Under the similarity regression framework, where the genetic effect is assessed by the model
significance that regresses trait similarity on genetic similarity, the variance component, τf, in
our CCRET model is equivalent to the regression coefficient of genetic similarity quantified by
the distance metric Kf(,).
Quantification of CNV similarity between two individuals
From the connection with other random-effects collapsing methods, we see that one can deter-
mine how to model the multi-locus CNV information by selecting the desired metrics (kernels)
to quantify similarity between subjects i and j. To fix the idea, consider the commonly used d-
th order polynomial function, i.e., Kf ðZfi ;Zfj Þ ¼ ð1þ
PMf
m¼1 wm  Zfim  ZfjmÞd , where wm is the
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pre-specified weight for locusm based on, for example, some inverse function of the allele fre-
quencies if CNVs of different frequency ranges are evaluated together. When d = 1, this corre-
sponds to the model with only main effects, i.e., hðZfi Þ ¼
PMf
m¼1 Zfm  Zfim; when d = 2, this
corresponds to a model with linear and quadratic main effects as well as two-way interactions,












‘m  Zfi‘  Zfim. For copy
number dosage, it may not be sensible to use directly ZDSim and plug it in to the kernel function
because both ZDSim < 2 and Z
DS
im > 2 deviate from normal copy number, while directly plugging
ZDSim implies a dosage effect with copy number 0 as baseline. To resolve this issue, when quanti-
fying similarity based on CNV dosage, we suggest to first covert ZDSim to a factorized design
vector GDSim . For example, for a dosage ranging from 0 to 4, we define a length-3 design
vector GDSim ¼ ½1 0 0 for dosage< 2, [0 1 0] for dosage = 2 and [0 0 1] for dosage> 2; then
Kf ðZDSi ;ZDSj Þ ¼ ð1þ
PMf
m¼1 wm  GDSimTGDSjm Þd . The factorized design vector naturally accommo-
dates the multi-categorical nature of dosage or GI. For discrete SNP data, one commonly used
distance metric is the identity-by-state (IBS) metric, which is the proportion of alleles shared
between two subjects in the targeted region. For CNV dosage, the IBS score at locusm becomes
GTimGjm and is indeed the linear kernel.
Evaluating dosage effects
Below we illustrate the details of the proposed CCRET method using CNV dosage effects as an
example, where we aim to assess the dosage effect while adjusting for the effects of CNV length
and CNV gene counts. Following Raychaudhuri et al. [27], we define ~ZGIn as the total number
of genes that are intersected (i.e., including disrupted and overlapped) by the CNVs for subject
i; define ~ZLeni as the mean CNV length in kb of subject i. For those subjects with no CNVs (i.e.,
~ZLeni ¼ 0), their ~ZLeni values are set to be the mean of the non-zero ~ZLen’i s. For dosage analysis,
we rewrite Model (1) as
gðm1iÞ ¼ g1Xi þ bLen~ZLeni þ bGI ~ZGIi þ hDSi ; ð2Þ
where hDS ¼ ðhDS1 ;    ; hDSn ÞT 
 Nð0; tDS KDSÞ and KDS is an n × nmatrix with
KDSði; jÞ ¼ KDSðZDSi ;ZDSj Þ. Under Model (2), the dosage effect can be evaluated by testing
HDS0 : tDS ¼ 0. The incorporation of the background CNV features when assessing dosage effect
is mainly for reducing the unexplained variance in the model and hence enhancing the detect-
ing power. Using a similar derivation as Tzeng et al. [17], we construct a score-based test statis-
tic to assess the dosage effect by considering a matrix presentation of Model (2):
gðm1Þ ¼ Xg1 þ ~ZLenbLen þ ~ZGIbGI þ hDS; ð3Þ
where μ1 = (μ11,  ,μ1n)T, X = (X1,  ,Xn)T, ~ZLen ¼ ðZ
 len1 ;    ; ~Zlenn ÞT , and
~ZGI ¼ ð~ZGI1 ;    ; ~ZGIn ÞT . Using a very similar derivation of Tzeng and Zhang [52] and Tzeng
et al. [17], it can be shown that the score test statistic is given as
TDS ¼
ðY  m1ÞTD1W1KDSW1D1ðY  m1ÞÞ
2
jtDS¼0; m1¼bm1; 1¼b1





 ¼ ðX; ~ZLen; ~ZGlÞ and θ1 = (γ1, βLen, βGI)T, Δ1 = diag{g0(μ1i)}, and
W1 = diag{w1i}, with w1i ¼ f1m11i b@ðy1iÞÞ½g 0ðm1iÞ2g
1
. Estimate by1 is the maximum likelihood
estimate (MLE) of θ1 under H0, and b1 is the restricted maximum likelihood (REML) type of
estimate of ϕ1 under H0. As shown in Tzeng and Zhang [52], and Tzeng et al. [17], TDS
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The corresponding p-values can be obtained by Davies’s methods (1980) [37] or by moment
matching approaches as discussed in [53].
Evaluating gene-intersection (GI) effects
A very similar procedure can be used to assess the gene-intersection effect while adjusting for
the effects of CNV length and the total number of CNV events. Specifically, we consider
gðm2iÞ ¼ g2Xi þ dLen~ZLeni þ dDS~ZDSi þ hGIi ; ð4Þ
where ~ZDSi is the total number of CNV events of subject i in the whole genome, ~Z
Len
i is as
defined before, hGI ¼ ðhGI1 ;    ; hGIn ÞT 
 Nð0; tGI KGIÞ and KGI is an n × nmatrix with
KGIði; jÞ ¼ KGIðZGIi ;ZGIj Þ. By a similar derivation as in the dosage analysis, the score statistics
for testing = 0 can be obtained as:
TGI ¼
ðY  m2ÞTD2W2KGIW2D2ðY  m2Þ
2
jtGI¼0; m2¼bm2 ; 2¼b2





 ¼ ðX; ~ZLen; ~ZDSÞ and θ2 = (γ2, δLen, δDS)T; Δ2,W2, by2 , and b are
defined in a fashion similar to the dosage test. The p-value of TGI can also be obtained by





1;‘, where the l2‘’s are the non-zero eigenvalues ofW2
12P2KGIP2W2
12 and












We evaluated the performance of CCRET using the PLINK methods (version 1.07, http://
pngu.mgh.harvard.edu/~purcell/plink/) as a benchmark. For dosage effect of the whole
genome, we compared CCRET with the burden-style methods [9] as implemented in PLINK
“—cnv-indiv-perm”. This method fits a regression model: (μi) = α0 + αc  ci, where ci is the
total number of events that are of interest (e.g., deletion, duplication, duplication+deletion etc.)
for individual i. The “—cnv-indiv-perm” evaluates the significance of αc via a permutation pro-
cedure. The default option returns 1-sided empirical p-values, assuming that the events of
interest are more common in cases than in controls (i.e. events increase risk). The default
1-sided tests have been commonly adopted in practice [8–12]. Adding the flag “—cnv-test-
2sided” will return 2-sided empirical p-values, allowing that the events of interest might be
more common either in cases or in controls. For the GI effect of a gene set, we compared
CCRET with the enrichment-style method of Raychaudhuri et al [27], which is implemented
as “—cnv-enrichment-test” test in PLINK. This method fits a logistic regression model:
gðmiÞ ¼ b0 þ bDS  ~ZDSi þ bLen  ~ZLeni þ bGI  gi, where ~ZDSi and ~ZLeni are as defined earlier, gi is
the total number of intersected genes in a predefined gene set and βf’s are regression coeffi-
cients. The “—cnv-enrichment-test” tests if βGI, the coefficient associated with GI counts, is sig-
nificantly different from 0. The default option returns 2-sided asymptotic p-values, allowing
that gene intersection might be more common either in cases or in controls.
Implementation
Source code of CCRET is available at http://www4.stat.ncsu.edu/~tzeng/software.php.
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